Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review
- PMID: 33769211
- PMCID: PMC8475568
- DOI: 10.1080/21645515.2021.1885282
Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review
Abstract
We described a 65-year-old male with choroidal metastases (CM) from non-small cell lung cancer (NSCLC). Pembrolizumab (Keytruda) combined with pemetrexed and capecitabine achieved excellent outcomes. After two cycles of pembrolizumab and chemotherapy, blurred vision and left eye pain were significantly relieved. Imaging and ophthalmologic examinations demonstrated complete resolution of the CM, as well as reduction of pulmonary shadow. CM from NSCLC shows complete and durable response to pembrolizumab and chemotherapy. We suggesting that immunotherapy combined with chemotherapy is a promising treatment for CM from NSCLC.
Keywords: Immunotherapy; choroidal metastases; non-small cell lung cancer; pembrolizumab.
Figures


Similar articles
-
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10. Lancet Oncol. 2016. PMID: 27745820 Free PMC article. Clinical Trial.
-
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2020 Mar;21(3):387-397. doi: 10.1016/S1470-2045(19)30801-0. Epub 2020 Feb 6. Lancet Oncol. 2020. PMID: 32035514 Clinical Trial.
-
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.J Clin Oncol. 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136. Epub 2020 Mar 9. J Clin Oncol. 2020. PMID: 32150489 Clinical Trial.
-
The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer.Expert Rev Respir Med. 2020 Feb;14(2):137-147. doi: 10.1080/17476348.2020.1702526. Epub 2019 Dec 17. Expert Rev Respir Med. 2020. PMID: 31815565 Review.
-
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.Immunotherapy. 2018 Feb;10(2):93-105. doi: 10.2217/imt-2017-0121. Epub 2017 Nov 17. Immunotherapy. 2018. PMID: 29145737 Review.
Cited by
-
Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review.Respirol Case Rep. 2023 Nov 30;12(1):e01262. doi: 10.1002/rcr2.1262. eCollection 2024 Jan. Respirol Case Rep. 2023. PMID: 38045825 Free PMC article.
-
How to Manage a Patient with Ocular Metastases?Biomedicines. 2022 Nov 25;10(12):3044. doi: 10.3390/biomedicines10123044. Biomedicines. 2022. PMID: 36551800 Free PMC article. Review.
-
[Staging and systemic treatment of ocular and periocular metastases].Ophthalmologie. 2024 May;121(5):374-381. doi: 10.1007/s00347-024-02034-4. Epub 2024 Apr 29. Ophthalmologie. 2024. PMID: 38683363 Review. German.
References
-
- Mathis T, Jardel P, Loria O, Delaunay B, Nguyen AM, Lanza F, et al. New concepts in the diagnosis and management of choroidal metastases. Prog Retin Eye Res. 2019;68:144–76. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical